However, it is known that metformin lowers activity in the mechanistic target of rapamycin (mTOR) and mitogen-activated protein kinase (MEK)-extracellular signal-regulated kinase (ERK) pathways, both of which are upregulated in FXS [163]. This evidence concerns the gene MTOR and fragile X syndrome.